Brasofensine

Brasofensine
	File:Brasofensine.png
Gene therapy
Clinical data
Physiological data
Legal status
Legal status	In general: legal;
Pharmacokinetic data
Identifiers
	IUPAC name 1-[(2R,3S)-3-(3,4-dichlorophenyl)-8-methyl -8-azabicyclo[3.2.1]octan-2-yl]-N-methoxymethanimine;
CAS Number	171655-91-7;
PubChem Template:Abbreviation	9554198;
Chemical and physical data
Formula	C16H20Cl2N2O
Molar mass	327.248 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN1C2CCC1C(C(C2)C3=CC(=C(C=C3)Cl)Cl)C=NOC;

Brasofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor. It has been researched for the treatment of Parkinson's Disease, depression and treatment of drug dependence. Phase II trials were conducted in 1996 and brasofensine was shown to be well tolerated at a dose of 4mg, but the current progress of this drug is unknown.^[1][1]

References

↑ Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002 Feb;36(2):225-30.